Cell therapy's poster child: Chimeric antigen receptor T cell therapy.

Author: Liling QIAN ¹ ; Jiangqing CHEN ¹ ; Xiaoyan WU ¹ ; Ruirui JING ¹ ; Jie SUN ¹
Author Information

1. Bone Marrow Transplantation Center of the First Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.
Publication Type:Journal Article
Keywords: cell therapy; chimeric antigen receptor T cell; immunotherapy; synthetic biology
MeSH: Cell- and Tissue-Based Therapy; Child; Humans; Immunotherapy; Immunotherapy, Adoptive; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocytes
From: Chinese Journal of Biotechnology 2019;35(12):2339-2349
CountryChina
Language:Chinese
Abstract: Chimeric antigen receptor T (CAR-T) cell therapy, which adoptively transfers engineered T cells expressing synthetic receptors to target specific antigens, has achieved great clinical success in treating hematological malignancies. Though FDA has approved two CAR-T products, CAR-T therapy can cause some side effects, such as cytokine release syndrome (CRS), neurotoxicity and B cell aplasia. Meanwhile, lacking tumor specific antigen and the suppressive tumor environment limit the efficacy of CAR-T therapy in solid tumor. This review focuses on the structural components, clinical applications and synthetic biology approaches on CAR-T cell design, and summarizes the challenges and perspectives of CAR-T therapy as a revolutionary cancer immunotherapy.